Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy

Little is known about key pathological events preceding overt neuronal degeneration in Parkinson's disease (PD) and α-synucleinopathy. Recombinant adeno-associated virus 2-mediated delivery of mutant (A53T) human α-synuclein into the substantia nigra (SN) under a neuron-specific synapsin promoter resulted in protracted neurodegeneration with significant dopaminergic (DA) neuron loss by 17 weeks. As early as 4 weeks, there was an increase in a dopamine metabolite, DOPAC and histologically, DA axons in the striatum were dystrophic with degenerative bulbs. Before neuronal loss, significant changes were identified in levels of proteins relevant to synaptic transmission and axonal transport in the striatum and the SN. For example, striatal levels of rabphilin 3A and syntaxin were reduced. Levels of anterograde transport motor proteins (KIF1A, KIF1B, KIF2A, and KIF3A) were decreased in the striatum, whereas retrograde motor proteins (dynein, dynamitin, and dynactin1) were increased. In contrast to reduced levels in the striatum, KIF1A and KIF2A levels were elevated in the SN. There were dramatic changes in cytoskeletal protein levels, with actin levels increased and α-/γ-tubulin levels reduced. In addition to these alterations, a neuroinflammatory response was observed at 8 weeks in the striatum, but not in the SN, demonstrated by increased levels of Iba-1, activated microglia and increased levels of proinflammatory cytokines, including IL-1β, IFN-γ and TNF-α. These results demonstrate that changes in proteins relevant to synaptic transmission and axonal transport coupled with neuroinflammation, precede α-synuclein-mediated neuronal death. These findings can provide ideas for antecedent biomarkers and presymptomatic interventions in PD.

[1]  Ole Isacson,et al.  Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease , 2004, Journal of Neuroinflammation.

[2]  Michael L. Kramer,et al.  Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[3]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[4]  J Q Trojanowski,et al.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Eric Jacobs,et al.  Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease , 2005, Annals of neurology.

[6]  A. Davies,et al.  Parkinson's disease α-synuclein mutations exhibit defective axonal transport in cultured neurons , 2004, Journal of Cell Science.

[7]  R. Mandel,et al.  The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease , 2008, Proceedings of the National Academy of Sciences.

[8]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[9]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Brundin,et al.  Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction , 2005, Neurobiology of Disease.

[11]  R. Llinás,et al.  1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C , 2007, Proceedings of the National Academy of Sciences.

[12]  Mark J. West,et al.  New stereological methods for counting neurons , 1993, Neurobiology of Aging.

[13]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[14]  H. Takagi,et al.  Loss of α-tubulin polyglutamylation in ROSA22 mice is associated with abnormal targeting of KIF1A and modulated synaptic function , 2007, Proceedings of the National Academy of Sciences.

[15]  Michael L. Kramer,et al.  Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies , 2007, The Journal of Neuroscience.

[16]  L. Swanson The Rat Brain in Stereotaxic Coordinates, George Paxinos, Charles Watson (Eds.). Academic Press, San Diego, CA (1982), vii + 153, $35.00, ISBN: 0 125 47620 5 , 1984 .

[17]  J. Ridet,et al.  alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Glass,et al.  Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man , 2004, Experimental Neurology.

[19]  J. Besson,et al.  Structural alteration and possible growth of afferents after kainate lesion in the adult rat thalamus , 1987, The Journal of comparative neurology.

[20]  C. Warren Olanow,et al.  Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.

[21]  Scott T. Brady,et al.  Neuropathogenic Forms of Huntingtin and Androgen Receptor Inhibit Fast Axonal Transport , 2003, Neuron.

[22]  H Li,et al.  Huntingtin Aggregate-Associated Axonal Degeneration is an Early Pathological Event in Huntington's Disease Mice , 2001, The Journal of Neuroscience.

[23]  Patrik Brundin,et al.  Loss of SNAP‐25 and rabphilin 3a in sensory‐motor cortex in Huntington’s disease , 2007, Journal of neurochemistry.

[24]  O. Isacson,et al.  Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease , 2008, Journal of Neuroinflammation.

[25]  Tudor A. Fulga,et al.  Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo , 2007, Nature Cell Biology.

[26]  J. Trojanowski,et al.  Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration , 2008, The Journal of Neuroscience.

[27]  M. Peschanski,et al.  Fetal homotypic transplant in the excitotoxically neuron‐depleted thalamus: Light microscopy , 1988, The Journal of comparative neurology.

[28]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[29]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[30]  C. Ferrari,et al.  Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease , 2008, Brain : a journal of neurology.

[31]  P. Lockhart,et al.  Oligomeric α-synuclein inhibits tubulin polymerization , 2007 .

[32]  P. Lockhart,et al.  Oligomeric alpha-synuclein inhibits tubulin polymerization. , 2007, Biochemical and biophysical research communications.

[33]  P. Apicella,et al.  Motor impairments and neurochemical changes after unilateral 6-hydroxydopamine lesion of the nigrostriatal dopaminergic system in monkeys , 1990, Neuroscience.

[34]  E. Masliah,et al.  Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer's Disease , 2005, Science.

[35]  M. Goldberg,et al.  Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration , 2008, The Journal of Neuroscience.

[36]  Lindsay N. Carpp,et al.  A role for the actin cytoskeleton in cell death and aging in yeast , 2004, The Journal of cell biology.

[37]  S. Endo,et al.  An Endogenous Serine/Threonine Protein Phosphatase Inhibitor, G-Substrate, Reduces Vulnerability in Models of Parkinson's Disease , 2007, The Journal of Neuroscience.